Table 2 First-generation phase III studies of adjuvant docetaxel in breast cancer

BCIRG-001 [20]

FAC × 6 versus TAC × 6

68% versus 75% (5-year); HR = 0.72, P = 0.001

81% versus 87% (5-year); HR = 0.70, P = 0.008

PACS-01 [21]

FEC × 6 versus FEC × 3 → D × 3

73% versus 78% (5-year); HR = 0.82, P = 0.012

87% versus 91% (5-year); HR = 0.73, P = 0.017

ECOG 2197 [22]

AC × 4 versus AD × 4

85% versus 85% (5-year); HR = 1.03, P = 0.78

91% versus 92% (5-year); HR = 1.06, P = 0.62

USO 9735 [23, 24]

AC × 4 versus DC × 4

75% versus 81% (7-year); HR = 0.74, P = 0.033

82% versus 87% (7-year); HR = 0.69, P = 0.032

BIG 02-98 [25]

A × 4 → CMF × 3 versus AC × 4 → CMF × 3 versus A × 3 → D × 3 → CMF × 3 versus AD × 4 → CMF × 3

D versus non-D: HR = 0.86, P = 0.051 Sequential D versus A-CMF: 78% versus 73% (5-year); HR = 0.79, P = 0.035 Concurrent AD versus AC-CMF: 74% versus 72% (5-year); HR = 0.93, P = 0.48 (NS)

NA

TAXIT 216 [26]

E × 4 → CMF × 4 versus E × 4 → D × 4 → CMF × 4

HR = 0.79, P = 0.0576

HR = 0.72, P = 0.0797

TACT [27]

FEC × 8 or E × 4 → CMF × 4 versus FEC × 4 → D × 4

74% versus 75% (4-year); HR = 0.97 (NS)

82% versus 82% (4-year); HR = 0.98 (NS)

GEICAM 9805 [28]

FAC × 6 versus TAC × 6

86% versus 91% (5-year); HR = 0.66, P = 0.02

95% versus 97% (5-year); HR = 0.72, P = 0.27

Mavroudis et al. [29]

FEC × 6 versus D × 4 → EC × 4

69% versus 75% (5-year); P = 0.029

-

WSG/AGO AM02 [30]

FEC × 6 versus EC × 4 → D × 4

85.8% versus 90.2% (5-year); HR = 1.51, P = 0.009

92.6% versus 94.8% (5-year); HR = 1.59, P = 0.04